In preclinical drug development, safety and efficacy data from animal models is a mandatory step in the process of turning lead compounds into drug candidates for human clinical trials.
To succeed, the right model systems must be chosen and, just as importantly, proper documentation must be done.
Programme
Learn more about what it takes to succeed in preclinical drug development form a highly experienced professional in the field.
Lindvi Gudmundsdotter
Lindvi is a highly experienced pharmaceutical professional with comprehensive accomplishments leading transformational change in novel biopharmaceutical development, deep tech, precision medicine, and cross-functional teams.
She is an innovative thinker with strong strategic, regulatory and translational medicine acumen with In-depth knowledge of biopharmaceuticals, ranging from vaccines to deep tech biotherapeutics utilized in precision medicine.
Lindvi’s long experience include among other things executive roles in Affibody AB, Strike Pharma AB and iCellate Medical AB.
Lindvi holds a PhD in microbiology from Karolinska Institutet.
SPARK Norway Educational Forum are monthly open meetings organized by UiO:Life Science and SPARK Norway partners.